A U.S. District Judge has accepted a guilty plea from Amgen (AMGN) and approved a $762M settlement to resolve criminal and civil liability arising from its illegal sale and misbranded promotion of Aranesp, which caused false claims to be submitted to Medicare, Medicaid and other government insurance programs. The settlement is the largest ever of its kind to involve a biotechnology firm.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs